Target intelligence / Profile preview

MAP/microtubule affinity-regulating kinase 2 (MARK2)

Target
MARK2
Molecular classification
Enzyme, Kinase, Serine/threonine-protein kinase
01

Overview

MAP/microtubule affinity-regulating kinase 2 (MARK2), also known as Par-1b, is a serine/threonine protein kinase belonging to the AMP-activated protein kinase (AMPK) family. It plays a fundamental role in establishing and maintaining cell polarity in epithelial and neuronal cells, as well as regulating microtubule dynamics by phosphorylating microtubule-associated proteins (MAPs) such as tau, MAP2, and MAP4. Phosphorylation of these proteins by MARK2 causes them to detach from microtubules, leading to microtubule destabilization and cytoskeletal remodeling. Additionally, MARK2 acts as a critical stress-sensing cytosolic regulator that phosphorylates eIF2alpha under proteotoxic stress, thereby modulating protein translation.\n\nIn disease states, MARK2 is heavily implicated in neurodegenerative disorders and oncology. In Alzheimer's disease, MARK2-mediated hyperphosphorylation of tau at Ser262 promotes the formation of neurofibrillary tangles and neurotoxicity. In amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), MARK2-eIF2alpha signaling is activated by misfolded proteins, promoting repeat-associated non-AUG (RAN) translation of toxic dipeptide repeats. In oncology, MARK2 is overexpressed in various malignancies, including pancreatic, ovarian, and breast cancers, where it supports tumor growth, metastasis, and chemoresistance (e.g., to paclitaxel and cisplatin) by regulating the Hippo/YAP pathway and class IIa HDACs. Pharmacological targeting of MARK2 is an active area of research, with small-molecule inhibitors like MRT199665, MARK-IN-2, and the tool compound 39621 being used to study its biology. Furthermore, the approved ALK inhibitor brigatinib has been identified as a potent off-target inhibitor of MARK2/3, offering potential drug repurposing opportunities for YAP/TAZ-dependent cancers.

Other names
Serine/threonine-protein kinase MARK2ELKL motif kinase 1EMK-1PAR1 homolog bPar-1bPar1bSer/Thr protein kinase PAR-1B
02

Mechanism of action

ATP-competitive inhibition of the kinase domain to block phosphorylation of downstream substrates such as tau, MAPs, and eIF2alpha.

03

Biological functions

Cell polarityMicrotubule dynamicsProtein phosphorylationCell cycle regulationTranslation regulationCytoskeletal organization
04

Disease associations

Neurodegenerative diseaseCancerAmyotrophic lateral sclerosisFrontotemporal dementiaAlzheimer's diseasePancreatic cancerOsteosarcomaOvarian cancer
05

Safety considerations

Immune dysfunction and autoimmunityDisruption of cell polarityImpairment of spatial learning and memoryAlterations of hypophyseal hormonesPotential embryonic lethality if combined with MARK3 inhibition
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

MARK2 expression levelTau phosphorylation at Ser262eIF2alpha phosphorylationYAP/TAZ activation statusHDAC4 phosphorylation

Beyond the preview

Go deeper on MAP/microtubule affinity-regulating kinase 2 (MARK2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAP/microtubule affinity-regulating kinase 2 (MARK2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call